Femke M. Feringa

Femke M. Feringa

Auto-generated profile, based on publicly available information

Femke M. Feringa

Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Molecular Cell
Verified
Journal Article
Closed access
LKLenno Krenning
Lenno Krenning
FFFemke M. Feringa
Femke M. Feringa
ISIndra A. Shaltiel
Indra A. Shaltiel
JBJeroen van Den Berg
Jeroen van Den Berg
RMRené H. Medema
René H. Medema

3 September 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JBJeroen van Den Berg
Jeroen van Den Berg
AMAnna G. Manjón
Anna G. Manjón
KKKaroline Kielbassa
Karoline Kielbassa
FFFemke M Feringa
Femke M Feringa
RFRaimundo Freire
Raimundo Freire
RMRené H. Medema
René H. Medema
DNA damaging agents cause a variety of lesions, of which DNA double-strand breaks (DSBs) are the most genotoxic. Unbiased approaches aimed at investigating the relationship between the number of DSBs and outcome of the DNA damage response have been challenging due to the random nature in which damage is induced by classical DNA damaging agents. Here, we describe a CRISPR/Cas9-based system that permits us to efficiently introduce DSBs at defined sites in the genome. Using this system, we show that a guide RNA targeting only a single site in the human genome can trigger a checkpoint response that is potent enough to delay cell cycle progression. Abrogation of this checkpoint leads to DNA breaks in mitosis which gives rise to aneuploid progeny.

25 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FFF. M. Feringa
F. M. Feringa
JRJ. A. Raaijmakers
J. A. Raaijmakers
MHM. A. Hadders
M. A. Hadders
CVC. Vaarting
C. Vaarting
LMLibor Macurek
Libor Macurek
RMRené H. Medema
René H. Medema
Double-stranded DNA breaks activate a DNA damage checkpoint in G2 phase to trigger a cell cycle arrest, which can be reversed to allow for recovery. However, damaged G2 cells can also permanently exit the cell cycle, going into senescence or apoptosis, raising the question how an individual cell decides whether to recover or withdraw from the cell cycle. Here we find that the decision to withdraw from the cell cycle in G2 is critically dependent on the progression of DNA repair. We show that delayed processing of double strand breaks through HR-mediated repair results in high levels of resected DNA and enhanced ATR-dependent signalling, allowing p21 to rise to levels at which it drives cell cycle exit. These data imply that cells have the capacity to discriminate breaks that can be repaired from breaks that are difficult to repair at a time when repair is still ongoing.

18 June 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
ALAnni Laine
Anni Laine
SNSrikar G. Nagelli
Srikar G. Nagelli
CFCaroline Farrington
Caroline Farrington
UBUmar Butt
Umar Butt
ACAnna N. Cvrljevic
Anna N. Cvrljevic
Jukka WestermarckJukka Westermarck
Jukka Westermarck
Basal-like breast cancers (BLBC) are characterized by defects in homologous recombination (HR), deficient mitotic checkpoint, and high-proliferation activity. Here, we discover CIP2A as a candidate driver of BLBC. CIP2A was essential for DNA damage–induced initiation of mouse BLBC-like mammary tumors and for survival of HR–defective BLBC cells. CIP2A was dispensable for normal mammary gland development and for unperturbed mitosis, but selectively essential for mitotic progression of DNA damaged cells. A direct interaction between CIP2A and a DNA repair scaffold protein TopBP1 was identified, and CIP2A inhibition resulted in enhanced DNA damage–induced TopBP1 and RAD51 recruitment to chromatin in mammary epithelial cells. In addition to its role in tumor initiation, and survival of BRCA-deficient cells, CIP2A also drove proliferative MYC and E2F1 signaling in basal-like triple-negative breast cancer (BL-TNBC) cells. Clinically, high CIP2A expression was associated with poor patient prognosis in BL-TNBCs but not in other breast cancer subtypes. Small-molecule reactivators of PP2A (SMAP) inhibited CIP2A transcription, phenocopied the CIP2A-deficient DNA damage response (DDR), and inhibited growth of patient-derived BLBC xenograft. In summary, these results demonstrate that CIP2A directly interacts with TopBP1 and coordinates DNA damage–induced mitotic checkpoint and proliferation, thereby driving BLBC initiation and progression. SMAPs could serve as a surrogate therapeutic strategy to inhibit the oncogenic activity of CIP2A in BLBCs.Significance: These results identify CIP2A as a nongenetic driver and therapeutic target in basal-like breast cancer that regulates DNA damage–induced G2–M checkpoint and proliferative signaling.

4 October 2018 in Journal of the American Chemical Society
Verified
Journal Article
Open access
MHMickel J. Hansen
Mickel J. Hansen
FFFemke M. Feringa
Femke M. Feringa
PKPiermichele Kobauri
Piermichele Kobauri
WSWiktor Szymanski
Wiktor Szymanski
RMRené H. Medema
René H. Medema
BFBen Feringa
Ben Feringa
Selectivity remains a major challenge in anticancer therapy, which potentially can be overcome by local activation of a cytotoxic drug. Such triggered activation can be obtained through modification of a drug with a photoremovable protecting group (PPG), and subsequent irradiation in the chosen place and time. Herein, the design, synthesis and biological evaluation is described of a photoactivatable MDM2 inhibitor, PPG-idasanutlin, which exerts no functional effect on cellular outgrowth, but allows for the selective, noninvasive activation of antitumor properties upon irradiation visible light, demonstrating activation with micrometer, single cell precision. The generality of this method has been demonstrated by growth inhibition of multiple cancer cell lines showing p53 stabilization and subsequent growth inhibition effects upon irradiation. Light activation to regulate protein–protein interactions between MDM2 and p53 offers exciting opportunities to control a multitude of biological processes and has the potential to circumvent common selectivity issues in antitumor drug development.

26 August 2016 in Nature Communications
Verified
Journal Article
Open access
FFFemke M. Feringa
Femke M. Feringa
LKLenno Krenning
Lenno Krenning
AKAndré Koch
André Koch
JBJeroen van Den Berg
Jeroen van Den Berg
Bram van den BroekBram van den Broek
Bram van den Broek
RMRené H. Medema
René H. Medema
Activation of the DNA-damage response can lead to the induction of an arrest at various stages in the cell cycle. These arrests are reversible in nature, unless the damage is too excessive. Here we find that checkpoint reversibility is lost in cells that are in very late G2, but not yet fully committed to enter mitosis (antephase). We show that antephase cells exit the cell cycle and enter senescence at levels of DNA damage that induce a reversible arrest in early G2. We show that checkpoint reversibility critically depends on the presence of the APC/C inhibitor Emi1, which is degraded just before mitosis. Importantly, ablation of the cell cycle withdrawal mechanism in antephase promotes cell division in the presence of broken chromosomes. Thus, our data uncover a novel, but irreversible, DNA-damage response in antephase that is required to prevent the propagation of DNA damage during cell division.